Myomo
Develops and markets MyoPro, a powered upper-limb orthosis (myoelectric brace) that restores arm and hand function for individuals with neuromuscular disorders, using 3D printing for component manufacturing.
- CEO / Founder
- Paul R. Gudonis
- Team Size
- 51-200
- Stage
- Public
- Total Funding
- $13.8M
- Latest Round
- IPO
- Key Investors
- Stonepine Capital Management; Manatuck Hill Partners
Technology & Products
Key Products
MyoPro; MyoPro 2x
Technological Advantage
Proprietary myoelectric control algorithms and patented technology (multiple patents in US, China, Hong Kong) provide a defensible position in the powered orthosis market. The use of 3D printing allows for rapid customization and cost-effective production, but the core advantage lies in the clinical efficacy and reimbursement coverage.
Differentiation
Value Proposition
Provides a non-invasive, wearable robotic device that enables patients to perform daily activities independently, reducing caregiver burden and improving quality of life; reimbursed by Medicare and private insurance.
How They Differentiate
Unlike exoskeletons for lower limbs, MyoPro focuses on upper-limb orthoses with myoelectric control, offering a lightweight, wearable solution that is reimbursed by insurance, whereas competitors often target different patient populations or require more invasive procedures.
Market & Competition
Target Customers
Patients with neurological disorders (e.g., stroke, brachial plexus injury), healthcare providers, orthotists, and prosthetists
Industry Verticals
Medical devices; Healthcare
Competitors
Ekso Bionics; ReWalk Robotics (Lifeward); Cyberdyne
Growth & Milestones
Growth Metrics
Revenue grew 83% YoY to $13.9 million in 2020; full-year 2026 revenue guidance of $43 million.
Major Milestones
2017: Completed IPO on NYSE MKT under Regulation A+; 2021: Formed joint venture with Beijing Ryzur Medical for China market; 2025: Launched MyoPro 2x
Notable Customers
Mayo Clinic; Cleveland Clinic; Massachusetts General Hospital; Kennedy Krieger Institute; Loma Linda Medical Center; VA hospitals (twenty)
Funding rounds
- Post-IPO$15M2024-12Source: Business Wire
- Venture Round$7M2013-10Source: PR